WHO Drug Information Vol. 15, No. 3 & 4, 2001: Regulatory and Safety Matters*: New communications and networking unit at EMEA

WHO Drug Information Vol. 15, No. 3 & 4, 2001
(2001; 76 pages)

Table of Contents

	WHO Drug Information
	Personal Perspectives
		Internet pharmacies: advantages and risks
	Reports on Individual Drugs
		Atypical antipsychotics and impaired glucose metabolism
		Antituberculosis drugs: hepatobiliary reactions
	Quality Assurance Issues
		WHO pilot pre-qualification project for pharmaceutical products
	Current Topics
		Antimicrobials in animal feed: a threat to human use
		Declaration of Helsinki and placebo-controlled clinical trials
	General Information
		Improving the quality and usefulness of drug regulatory authority websites
	Regulatory and Safety Matters*
		Infliximab and congestive heart failure
		Infliximab: warning of opportunistic infections
		Brimonidine ophthalmic drops: accidental ingestion
		P-Glycoprotein and drug interaction
		Nonacog alfa: intensive surveillance
		Tenofovir disoproxil fumarate approved for HIV infection
		Ciprofloxacin hydrochloride for inhalation anthrax
		DTPa and limb swelling
		Nitrofurantoin and peripheral neuropathy
		Continued suspension for tolcapone
		MMR vaccine and idiopathic thrombocytopenic purpura
		New communications and networking unit at EMEA
	ATC/DDD Classification
		Final list
		Temporary list
	Regulatory Information
		Internet purchase of pharmaceuticals: a review of regulatory experience*
	Recommended International Nonproprietary Names (rec. Inn): List 46
	Selected WHO Publications of Related Interest

New communications and networking unit at EMEA

European Union - The European Agency for the Evaluation of Medicinal Products (EMEA) has announced the creation of a new unit with responsibility for facilitating communications and networking between the Agency’s partners. This will reinforce the networking character of the EMEA by focusing on communication tools and IT systems needed to bring the Agency closer to the 27 different competent authorities in Member countries. The IT systems will allow secure regulatory exchange between authorities and industry during submission and evaluation of medicines.

Reference: EMEA Press Release. 18 October 2001. http://www.emea.eu.int